hypocrisy

Its amazing how fickle and hypocritical the market is...

...ACL was hovering between approx 60-70c in the year leading-up to Fonda approval. With approval and surprise that there was to be a third drug sharing the spoils and some subsequent announcement gaffs, etc, the market has subsequently forgotten that cash is starting to line the coffers and that 30-40% of the market (this percentage being shared with DR) instead of say, 60%, is still not bad.

Show's how important market momentum is - momentum is not just determined by revenue - the way a company educates the market is just as important.

Anyway, here we are, waiting to get back to where we were a year out from approval.

Bring on the sales data!